EGFR and non-small cell lung carcinoma: CameL (NCT03134872) was a randomized, open-label, phase III trial evaluating the efficacy of camrelizumab combined with carboplatin and pemetrexed in Chinese treatment-naïve patients with advanced nonsquamous NSCLC without EGFR and ALK alterations.